SCHEMBL14927282

SCHEMBL14927282

Cc1cc(C)cc(NC(=O)c2cc(-c3ccc(Cl)cc3)oc2C(F)(F)F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.57
MAPT P10636 4/20 0.57
MCHR1 Q99705 1/20 0.53
TMPRSS4 Q9NRS4 2/20 0.50
P2RX1 P51575 1/20 0.50
SCN10A Q9Y5Y9 4/20 0.48
KCNH2 Q12809 1/20 0.48
SCN2A Q99250 2/20 0.46
HTR1A P08908 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CNR1 P21554 1/20 0.46
DRD1 P21728 1/20 0.46
HTR2A P28223 1/20 0.46
ADORA2A P29274 1/20 0.46
OPRM1 P35372 1/20 0.46
SCN5A Q14524 1/20 0.46
SCN9A Q15858 1/20 0.46
SCN3A Q9NY46 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14927279 0.93 KDM4E (0.54) KDM4EMAPTMCHR1TMPRSS4P2RX1
SCHEMBL16171175 0.93 KDM4E (0.54) KDM4EMAPTMCHR1TMPRSS4P2RX1
SCHEMBL14927269 0.88 SCN10A (0.48) KDM4EMAPTMCHR1TMPRSS4P2RX1
SCHEMBL14927268 0.88 DGAT1 (0.56) KDM4EMAPTSCN10ADGAT1HPGD
SCHEMBL898265 0.87 P2RX1 (0.57) KDM4EMAPTMCHR1TMPRSS4P2RX1
SCHEMBL14927284 0.87 KDM4E (0.55) KDM4EMAPTMCHR1TMPRSS4P2RX1
SCHEMBL313321 0.84 MAPT (0.57) KDM4EMAPTMCHR1TMPRSS4P2RX1
SCHEMBL898601 0.83 KDM4E (0.52) KDM4EMAPTMCHR1TMPRSS4P2RX1
SCHEMBL14927272 0.82 MAPT (0.44) KDM4EMAPTMCHR1TMPRSS4P2RX1
SCHEMBL16171121 0.82 TMPRSS4 (0.49) KDM4EMAPTTMPRSS4P2RX1SCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663483-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2017-05-30 US disclosed
US-9149527-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2015-10-06 US disclosed
US-20140309297-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2014-10-16 US disclosed
US-8722731-B2 Furanyl compounds and the use thereof NOVOMEDIX, LLC (US) 2014-05-13 US disclosed
US-20130116317-A1 FURANYL COMPOUNDS AND THE USE THEREOF NOVOMEDIX, LLC (US) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116317-A1 FURANYL COMPOUNDS AND THE USE THEREOF EIF4EBP1, EIF4E, EIF4A1 KDM4E 423/4885MAPT 4064/4885MCHR1 4041/4885
US-20140309297-A1 FURANYL COMPOUNDS AND THE USE THEREOF EIF4EBP1, EIF4E, GLI1 KDM4E 369/4885MAPT 3803/4885MCHR1 4078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.